Brii Biosciences' (HKG:2137) attributable loss widened to 508.2 million yuan in 2024 from 174.8 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Loss per share at the drug company widened to 0.70 yuan from 0.24 yuan in the previous year.
The company did not recognize revenue during the year. In the year-ago period, revenue was 617,000 yuan.
Other income fell to 141.4 million yuan from 163.7 million yuan a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.